Advances in reseach on Mycobacterium tuberculosis drug resistance mechanism

Abstract

Abstract: Tuberculosis was one of most serious infectious diseases that were harmful to human health. Antibiotics was effective treatment against this bacterium. But the emergency of multi- and extensively drug-resistant Mycobacterium tuberculosis(Mtb) were occurred frequently when the use of antibiotics was unproper. Drugresistant phenotype was due to mutations in drug resistant related genes, this paper will state the progress in mechanism study of drug resistant Mtb, which will guide the diagnosis and treatment of drug resistant Mtb.

Key words: Antitubercular agents, Antibiotics, antitubercular, Drug resistance, bacterial

DING Hai-rong, QIN Chuan, ZHAN Ling-jun. Advances in reseach on Mycobacterium tuberculosis drug resistance mechanism[J]. Chinese Journal of Antituberculosis, 2013, 35(8): 615-620.

References

［1］全国第五次结核病流行病学抽样调查技术指导组,全国第五次结核病流行病学抽样调查办公室. 2010年全国第五次结核病流行病学抽样调查报告.中国防痨杂志，2012,34（8）：485-508.
［2］Wirth T, Hildebrand F, Allix-Béguec C, et al.Origin, spread and demography of the Mycobacterium tuberculosis complex. PLoS Pathog,2008,4(9):e1000160.
［3］Motiwala AS, Dai Y, Jones-López EC,et al. Mutations in extensively drug-resistant Mycobacterium tuberculosis that do not code for known drug-resistance mechanisms.J Infect Dis,2010,201(6):881-888.
［4］Marttila HJ,Soini H,Eerola E,et al.A Ser315 Thr substitution in katG is predominant in genetically heterogeneous multidrug-resistant Mycobacterium tuberculosis isolates originating from the St.Petersburg area in Russia.Antimicrob Agents Chemother,1998,42(9):2443-2445.
［5］Coll P, Aragón LM, Alcaide F,et al.Molecular analysis of isoniazid and rifampin resistance in Mycobacterium tuberculosis isolates recovered from Barcelona. Microb Drug Resist,2005,11（2）:107-114.
［6］Haas WH, Schilke K, Brand J, et al. Molecular analysis of katG gene mutations in strains of Mycobacterium tuberculosis complex from Africa.Antimicrob Agents Chemother，1997,41（7）:1601-1603.
［7］Musser JM, Kapur V, Williams DL, et al. Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance.J Infect Dis，1996,173（1）:196-202.
［8］Rouse DA,Morris SL. Molecular mechanisms of isoniazid resistance in Mycobacterium tuberculosis and Mycobacterium bovis.Infect Immun,1995,63(4):1427-1433.
［9］Lee AS, Tang LL, Lim IH,et al.Lack of clinical significance for the common arginine-to-leucine substitution at codon 463 of the katG gene in isoniazid-resistant Mycobacterium tuberculosis in Singapore.J Infect Dis，1997,176（4）:1125-1126.
［10］Cockerill FR 3rd, Uhl JR, Temesgen Z, et a1．Rapid identification of a point mutation of the Mycobacterium tuberculosis catalase-peroxidase(KatG)gene associated with isoniazid resistance．J Infect Dis,1995，171(1)：240-245.
［11］Banerjee A, Dubnau E, Quemard A,et al.inhA,a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science，1994,263(5144):227-230.
［12］Dessen A, Quémard A, Blanchard JS, et al. Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis. Science,1995,267（5204）:163-1641.
［13］Rozwarski DA, Grant GA, Barton DH, et al.Modification of the NADH of the isoniazid target(inhA)from Mycobacterium tuberculosis. Science,1998,279（5347）:98-102.
［14］Zhang Y,Young D. Molecular genetics of drug resistance in Mycobacterium tuberculosis.J Antimicrob Chemother,1994,34(3):313-319.
［15］Morlock GP,Metchock B,Sikes D,et al.ethA,inhA,and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother, 2003, 47(12): 3799-3805.
［16］Ano H,Matsumoto T,Nangi T,et al.Resistance-conferring mutations of Mycobacterium tuberculosis strains with low level resistance to isoniazid. Kekkaku,2006,81(12):709-713.
［17］Guo H,Seet Q,Denkin S,et al. Molecular characterization of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from the USA.J Med Microbiol, 2006,55(Pt 11):1527-1531.
［18］Larsen MH, Vilchèze C, Kremer L, et al.Overexpression of inhA,but not kasA,confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M.Bovis BCG and M.tuberculosis. Mol Microbiol,2002,46(2):453-466.
［19］Lee AS,Lim IH,Tang LL,et al.Contribution of kasA analysis to detection of isoniazid-resistant Mycobacterium tuberculosis in Singapore.Antimicrob Agents Chemother,1999,43(8):2087-2089.
［20］Piatek AS,Telenti A,Murray MR,et al.Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons:implications for rapid susceptibility testing.Antimicrob Agents Chemother,2000,44(1):103-110.
［21］Lee AS, Teo AS, Wong SY.Novel mutations in ndh in isoniazid-resistant Mycobacterium tuberculosis isolates.Antimicrob Agents Chemother,2001,45(7):2157-2159.
［22］Enne VI,Delsol AA,Roe JM,et al.Rifampicin resistance and its fitness cost in Enterococcus faecium. J Antimicrob Chemother,2004,53(2):203-207.
［23］Lee JH,Ammerman NC,Nolan S,et al.Isoniazid resistance without a loss of fitness in Mycobacterium tuberculosis.Nat Commun,2012,3(753):1-8.
［24］Viader-Salvadó JM, Luna-Aguirre CM, Reyes-Ruiz JM,et al.Frequency of mutations in ropB and codons 315 and 463 of katG in rifampin- and/or isoniazid-resistant Mycobacterium tuberculosis isolates from northeast Mexico.Microb Drug Resist,2003,9(1):33-38.
［25］Mokrousov I,Narvskaya O,Otten T,et al.High prevalence of KatG Ser315Thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates from morthwestern Russia,1996 to 2001.Antimicrob Agents Chemother, 2002, 46(5):1417-1424.
［26］熊札宽.结核病实验诊断学.北京：人民卫生出版社，2008：54-68.
［27］Moghazeh SL,Pan X,Arain T,et al.Comparative antimycobacterial activities of riampin,rifapentine,and KRM-1648 against a collection of rifamin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob Agents Chemother,1996,40(11):2655-2657.
［28］Ohno H,Koga H,Kohno S,et al.Relationship between rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan. Antimicrob Agents Chemother,1996,40(4):1053-1056.
［29］徐瑛.耐多药结核病研究进展.预防医学情报杂志,2008,24(4):290-292.
［30］Zhang Y,Mitchison D. The curious characteristics of pyrazinamide: a review.Int J Tuberc Lung Dis,2003,7(1):6-21.
［31］Unissa AN,Selvakumar N,Hassen S.Insight to pyrazinamide resistance in Mycobacterium tuberculosis by molecular docking. Bioinformation,2009,4(1):24-29.
［32］Petrella S,Gelus-Ziental N,Maudry A,et al.Crystal structrure of the pyrazinamidase of Mycobacterium tuberculosis:insights into natural and acquired resistance to pyrazinamide.PLoS One,2011,6(1）：1-8.
［33］洪创跃，刘小立，桂静，等.耐多药结核分枝杆菌pncA基因突变特征及与吡嗪酰胺耐药相关性研究.中华预防医学杂志,2012,46(5)：436-439.
［34］Cuevas-Córdoba B, Xochihua-González SO, Cuellar A, et al. Characterization of pncA gene mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from Mexico.Infect Genet Evol,2013, pii: S1567-1348(12)00395-4.
［35］Shi W,Zhang X,Jiang X,et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis.Science,2011,333(6049):1630-1632.
［36］Mokrousov I,Otten T,Vyshnevskiy B,et al. Detection of embB306 mutations in ethambutol-susceptible clinical isolates of Mycobacterium tuberculosis from Northwestern Russia: implications for genotypic resistance testing.J Clin Microbiol,2002,40(10):3810-3813.
［37］Ramaswamy SV, Amin AG, Gksel S, et al.Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis.Antimicrob Agents Chemother,2000,44(2):326-336.
［38］Dobner P, Bretzel G, Rüsch-Gerdes S, et al.Geographic variation of the predictive values of genomic mutations associated with streptomycin resistance in Mycobacterium tuberculosis.Mol Cell Probes,1997,11(2):123-126.
［39］Okamoto S, Tamaru A, Nakajima C, et al. Loss of a conserved 7-methylguanosine modification in 16S rRNA confers low-level streptomycin resistance in bacteria. Mol Microbiol,2007,63(4):1096-1106.
［40］Maus CE,Plikaytis BB,Shinnick TM.Molecular analysis of cross-resistance to capreomycin,kanamycin,amikacin,and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother,2005,49(8):3192-3197.
［41］Zaunbrecher MA,Sikes RD Jr,Metchock B,et al.Over expression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A,2009,106(47):20004-20009.
［42］刘雪梅，谢建平.卷曲霉素作用机制和耐药机制的功能基因组学研究进展.药学学报,2008,43(8):788-792.
［43］Giannoni F,Iona E,Sementilli F,et al.Evaluation of a new line probe assay for rapid identification of gyrA mutations in Mycobacterium tuberculosis.Antimicrob Agents Chemother,2005,49(7):2928-2933.
［44］李国利，陈澎，孙昌文,等.结核分枝杆菌对左氧氟沙星与莫西沙星的交叉耐药性及gyrA和gyrB基因突变分析.中国防痨杂志,2010,32(10):616-621.
［45］Hegde SS, Vetting MW, Roderick SL, et al, A fluoroquinolone resistance protein from Mycobacterium tuberculosis that mimics DNA. Science,2005,308(5727):1480-1483.
［46］Buriánková K, Doucet-Populaire F, Dorson O, et al. Molecular basis of intrinsic macrolide resistance in the Mycobacterium tuberculosis complex. Antimicrob Agents Chemother,2004,48(1):143-150.
［47］Hillemann D, Rüsch-Gerdes S, Richter E. In vitro-selected linezolid-resistant Mycobacterium tuberculosis mutants. Antimicrob Agents Chemother, 2008,52(2):800-801.

[1]	Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Inspire-CODA Research Group. Expert consensus on the treatment of tuberculosis with contezolid [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 123-129.
[2]	Li Xuelian, Zhang Hongyan, Wang Jun, Wang Qingfeng, Ma Liping, Chu Naihui, Nie Wenjuan. Safety of extended delamanid use in drug-resistant tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 164-168.
[3]	Shi Lulu, Jing Hui, Liang Min, Li Xuezheng. Analysis of clinical results of blood concentration detection of antituberculosis drugs by liquid chromatography-tandem mass spectrometry [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 886-891.
[4]	Duan Shujuan, Wang Wei, Pang Yu, Li Ling. Research progress on the regulation of host anti-tuberculosis effect by tyrosine kinase inhibitors [J]. Chinese Journal of Antituberculosis, 2024, 46(5): 584-589.
[5]	Jiayinati Jingesi, Wang Xinqi, Liu Nianqiang, Wang Senlu, Yipaer Aihaiti, Feng Jianyu, Huang Tao, Kedieryekezi Wufuer. Analysis of treatment completeness and its influencing factors of preventive treatment among 387 latent tuberculosis infection cases [J]. Chinese Journal of Antituberculosis, 2024, 46(12): 1496-1503.
[6]	Shi Chunjing, Liu Xing, Li Longfen, Li Wenming, Zhang Huajie, Wang Ge, Zeng Haiyan, Liu Li, Shen Lingjun. Research progress on the effects of bedaquiline,delamanid and pretomanid on liver function in the treatment of multidrug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(12): 1560-1565.
[7]	Sha Wei. Significance and challenges of the implementation of PAN-TB treatment strategy for tuberculosis prevention and control [J]. Chinese Journal of Antituberculosis, 2024, 46(10): 1188-1192.
[8]	Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis, Beijing Chest Hospital, Capital Medical University. Expert consensus on clinical monitoring and management of QTc interval prolongation caused by anti-tuberculous drugs [J]. Chinese Journal of Antituberculosis, 2024, 46(1): 8-17.
[9]	Wang Honghong, Guo Shaochen, Zhou Wenqiang, Liu Zhongquan, Zhu Hui, Lu Yu. Influence of linezolid blood concentration on hematological toxicity in drug-resistant tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2023, 45(2): 165-171.
[10]	Chen Fang, Zhang Xiaofo, Zhou Haiyi, Zhang Feng, Wang Manzhi. Analysis of status and influencing factors associated with anti-tuberculosis drug-related liver injury in children [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 45-51.
[11]	LIU Hai-ting, LI Dong-shuo, ZHANG Lei, WANG Ning, WANG Bin, DING Yang-ming, YAO Rong, LU Yu. A preliminary study on the synergy and mechanism of pyrifazimine and bedaquiline [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 646-653.
[12]	LU Ni-hong, SHEN Ling-jun, LIU Hong-lu, CHEN Yang-jun, YANG Yan, DU Ying-rong. Clinical value of ESAT-6, immune and inflammatory indexes in the diagnosis of anti-tuberculosis drug-induced liver injury [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 654-659.
[13]	NIE Wen-juan, ZHOU Wen-qiang, CHU Nai-hui. Research progress on pharmacokinetics and drug interaction of bedaquiline [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 716-719.
[14]	XUE Yu, ZHANG Jing, NIE Wen-juan. The efficacy and safety of regimen containing bedaquiline in the treatment of elderly drug-resistant tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2022, 44(6): 582-586.
[15]	LIANG Li, ZOU Li-ping, XIE Fang-hui, CHEN Qing, WU Gui-hui. Three cases of anti-tuberculosis therapy-associated acute liver failure in tuberculosis children and literature review [J]. Chinese Journal of Antituberculosis, 2022, 44(4): 343-348.